Type IIIb Endoleak Might Be the Next Concern in Cases of EVAR Without Type II Endoleak

We previously demonstrated the efficacy of endovascular aortic aneurysm repair (EVAR) using concomitant n-butyl-2-cyanoacrylate (NBCA) injection into the abdominal aortic aneurysm sac to prevent a type II endoleak (T2E) from lumbar arteries. Although T2E as the leading cause of secondary interventions was under control, EVAR, even without a type I endoleak, does not guarantee satisfactory mid-term outcomes. The aim of this study was to report our intraoperative T2E management and propose the next target to reduce secondary interventions following EVAR.